Eric T Williams

Summary

Affiliation: Eisai Medical Research
Country: USA

Publications

  1. ncbi Investigation of the metabolism of rufinamide and its interaction with valproate
    Eric T Williams
    Eisai Inc, Andover, Massachusetts 01810, USA
    Drug Metab Lett 5:280-9. 2011
  2. doi Genomic analysis of the carboxylesterases: identification and classification of novel forms
    Eric T Williams
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Mol Phylogenet Evol 57:23-34. 2010
  3. doi Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human
    Eric T Williams
    Department of Drug Disposition, Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Drug Metab Dispos 39:2305-13. 2011
  4. doi Effect of buffer components and carrier solvents on in vitro activity of recombinant human carboxylesterases
    Eric T Williams
    Department of Drug Disposition, Lilly Research, Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, United States
    J Pharmacol Toxicol Methods 57:138-44. 2008
  5. doi The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2
    Eric T Williams
    Department of Drug Disposition, Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Drug Metab Dispos 36:1227-32. 2008
  6. doi Reversible inhibition of human carboxylesterases by acyl glucuronides
    Natalie R Inoue
    Eisai Inc, Andover, Massachusetts, USA
    Drug Metab Dispos 41:698-703. 2013
  7. ncbi In vitro screening of metabolic clearance using two concentration points
    Eric T Williams
    DMPK Andover, Eisai Inc, 4 Corporate Drive, Andover, MA 01810, USA
    Drug Metab Lett 4:233-40. 2010

Detail Information

Publications7

  1. ncbi Investigation of the metabolism of rufinamide and its interaction with valproate
    Eric T Williams
    Eisai Inc, Andover, Massachusetts 01810, USA
    Drug Metab Lett 5:280-9. 2011
    ..Carboxylesterases were not significantly inhibited by CGP 47292. Inhibition of in vitro rufinamide hydrolysis by valproate could offer an explanation for the observed in vivo drug-drug interaction between the two antiepileptic drugs...
  2. doi Genomic analysis of the carboxylesterases: identification and classification of novel forms
    Eric T Williams
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Mol Phylogenet Evol 57:23-34. 2010
    ..Finally, this study presents considerations for a broader phylogenetic-based nomenclature that could encompass other serine hydrolases in addition to the CEs...
  3. doi Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human
    Eric T Williams
    Department of Drug Disposition, Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Drug Metab Dispos 39:2305-13. 2011
    ..Loperamide, a selective human CES2 inhibitor, was also found to be a CES2-selective inhibitor in both dog and monkey. This is the first study to examine substrate specificity among dog, human, and monkey CESs...
  4. doi Effect of buffer components and carrier solvents on in vitro activity of recombinant human carboxylesterases
    Eric T Williams
    Department of Drug Disposition, Lilly Research, Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, United States
    J Pharmacol Toxicol Methods 57:138-44. 2008
    ..Therefore, it is unknown if the many different assay conditions used by various laboratories have a substantial impact on the activity of CE enzymes...
  5. doi The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2
    Eric T Williams
    Department of Drug Disposition, Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Drug Metab Dispos 36:1227-32. 2008
    ..These data help explain the rapid appearance of R-138727 in human plasma, where maximum concentrations are observed 0.5 h after a prasugrel p.o. dose, and the rapid onset of action of prasugrel...
  6. doi Reversible inhibition of human carboxylesterases by acyl glucuronides
    Natalie R Inoue
    Eisai Inc, Andover, Massachusetts, USA
    Drug Metab Dispos 41:698-703. 2013
    ..Conclusion: Drug-drug interaction studies may be warranted for drugs that metabolize to acyl glucuronides due to the potential inhibition of hCESs...
  7. ncbi In vitro screening of metabolic clearance using two concentration points
    Eric T Williams
    DMPK Andover, Eisai Inc, 4 Corporate Drive, Andover, MA 01810, USA
    Drug Metab Lett 4:233-40. 2010
    ..On the other hand, compounds with relatively low metabolic rates yielded more variable results. Thus, the use of two substrate concentrations should be useful with screening assays for assessing the kinetic values for other compounds...